School of Statistics, University of International Business and Economics, Beijing, China.
Graduate Institute of Business Administration, Fu Jen Catholic University, Taipei, Taiwan.
Cancer Med. 2018 Aug;7(8):4104-4114. doi: 10.1002/cam4.1685. Epub 2018 Jul 15.
Recurrent aphthous stomatitis (RAS) is considered a prophase symptom in patients with specific cancers. This study assessed the association between RAS and subsequent onset of cancer based on a nationwide population-based database in Taiwan.
We selected study participants from the National Health Insurance Research Database from January 2000 to December 2008. Patients in the non-RAS cohort were matched to case study patients at a 1:1 ratio through frequency matching. All participants were followed up for at least 5 years, and those who received cancer diagnoses during follow-up were identified.
Among 52 307 patients with and 52 304 patients without RAS, the combined hazard ratio (HR) of all subsequent cancer cases was 1.3 (95% confidence interval [CI]: 1.25-1.35, P = 0). RAS diagnosis was associated with risk for cancers of the head and neck (aHR = 2, 95% CI: 1.8-2.3), colon (aHR = 1.2, 95% CI: 1.1-1.4), liver (aHR = 1.1, 95% CI: 1-1.3), pancreas (aHR = 1.4, 95% CI: 1.1-1.7), skin (aHR = 1.4, 95% CI: 1.2-1.7), breast (aHR = 1.2, 95% CI: 1.1-1.4), and prostate (aHR = 1.5, 95% CI: 1.3-1.8), as well as hematologic cancers (aHR = 1.6, 95% CI: 1.3-1.9). A higher risk was observed for male patients (aHR = 1.35, 95% CI: 1.28-1.42) than for female patients (aHR = 1.25, 95% CI: 1.18-1.31) with RAS.
RAS was associated with specific cancers. Susceptible RAS patients should be screened for specific cancers.
复发性阿弗他口炎(RAS)被认为是特定癌症患者的前期症状。本研究基于台湾的全国人群数据库评估了 RAS 与随后发生癌症之间的关联。
我们从 2000 年 1 月至 2008 年 12 月的国家健康保险研究数据库中选择了研究参与者。非 RAS 队列中的患者通过频率匹配与病例研究患者以 1:1 的比例匹配。所有参与者均至少随访 5 年,并确定随访期间被诊断为癌症的患者。
在 52307 例患有 RAS 和 52304 例无 RAS 的患者中,所有后续癌症病例的合并危险比(HR)为 1.3(95%置信区间[CI]:1.25-1.35,P=0)。RAS 诊断与头颈部(aHR=2,95%CI:1.8-2.3)、结肠(aHR=1.2,95%CI:1.1-1.4)、肝脏(aHR=1.1,95%CI:1-1.3)、胰腺(aHR=1.4,95%CI:1.1-1.7)、皮肤(aHR=1.4,95%CI:1.2-1.7)、乳房(aHR=1.2,95%CI:1.1-1.4)和前列腺(aHR=1.5,95%CI:1.3-1.8)癌症以及血液系统癌症(aHR=1.6,95%CI:1.3-1.9)的风险增加。与 RAS 相关的男性患者(aHR=1.35,95%CI:1.28-1.42)的风险高于女性患者(aHR=1.25,95%CI:1.18-1.31)。
RAS 与特定癌症有关。易感 RAS 患者应筛查特定癌症。